BC Extra | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's neurology portfolio and gives...
BC Week In Review | Sep 14, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BC Extra | Sep 13, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BC Innovations | Jun 25, 2015
Emerging Company Profile

Light-speed electrophysiology

The inability of standard electrophysiological methods to detect high resolution signals in a large number of cells simultaneously has hampered the development of new therapies for neurological and cardiac diseases. Q-State Biosciences Inc. 's high...
BC Extra | Apr 23, 2015
Financial News

SciFluor raises $30M in series A

Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an untranched series A round led by new investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated...
BioCentury | Aug 1, 2011
Finance

Not so fast

Not so fast Merlin Nexus LP and New Leaf Ventures think the 150% premium that Pfizer Inc. (NYSE:PFE) has offered to pay for Icagen Inc. (NASDAQ:ICGN) "dramatically undervalues" the pain company's assets, and sent a...
BC Week In Review | Feb 7, 2011
Clinical News

ICA-105665: FDA action

Icagen said FDA lifted a clinical hold on ICA-105665 after reviewing the proposed protocol for a Phase II trial and data from recently completed clinical trials. Further details were not disclosed. Last October, FDA placed...
BC Week In Review | Oct 11, 2010
Clinical News

ICA-105665: FDA hold

FDA placed a clinical hold on ICA-105665 after Icagen reported last month that 1 patient experienced an undisclosed serious adverse event after receiving a single 600 mg dose of the compound in a single-blind, placebo-controlled,...
BC Week In Review | Sep 20, 2010
Clinical News

ICA-105665: Phase I data

A placebo-controlled, multiple ascending-dose Phase I trial in 32 healthy volunteers showed that no serious adverse events were reported in subjects receiving daily doses of 500 and 600 mg ICA-105665 for 7 days. Last year,...
BC Week In Review | Sep 20, 2010
Clinical News

ICA-105665: Suspended Phase IIa enrollment

Icagen suspended further enrollment in a single-blind, placebo-controlled, dose-ranging, U.S. Phase IIa trial after reporting that 1 patient experienced an undisclosed serious adverse event after receiving a single 600 mg dose of ICA-105665. The trial...
Items per page:
1 - 10 of 22